COMMUNIQUÉS West-GlobeNewswire

Healthcare Champions Launch Public Education Campaign to Address New Mexico’s Medical Access Crisis
01/09/2025
Santa Fe, NM, Sept. 01, 2025 (GLOBE NEWSWIRE) -- A new public education campaign has been launched by Patient-Led NM, founded by the New Mexico Medical Society, New Mexico Hospital Association, Sacramento Mountains [...]
Idorsia furthers the science of sleep and insomnia at World Sleep 2025
01/09/2025
Allschwil, Switzerland – September 1, 2025 Idorsia Ltd (SIX: IDIA) continues its commitment to furthering the science of sleep and insomnia with a symposium and eight poster presentations at World Sleep 2025, a global [...]
EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 31 juillet 2025
01/09/2025
Nombre total de droits de vote et d’actions composant le capital social au 31 juillet 2025 (Conformément à l’article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l’AMF) Paris, [...]
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of July 31, 2025
01/09/2025
Disclosure of Share Capital and Voting Rights Outstanding as of July 31, 2025 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]
Grant of Warrants
01/09/2025
September 1, 2025 Announcement no. 20 Grant of Warrants Copenhagen, Denmark, September 1, 2025, (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) has today decided to [...]
KFSHRC to Participate as Strategic Partner in C3 Davos of Healthcare New York Summit
01/09/2025
NEW YORK, Sept. 01, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) is participating as a Strategic Partner in the C3 Davos of Healthcare New York Summit, “Healthcare Disrupted: [...]
Communiqué de presse : Yves Jacob nommé responsable R&D France de Sanofi à compter du 1er septembre
01/09/2025
Yves Jacob nommé responsable R&D France de Sanofi à compter du 1 er septembre Gentilly (France), le 1 er septembre 2025 – Sanofi annonce la nomination d’ Yves Jacob en tant que Responsable R&D France . Yves [...]
Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences
01/09/2025
ZUG, Switzerland, Sept. 01, 2025 (GLOBE NEWSWIRE) -- Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session Expanded data analysis from Phase 3 [...]
Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences
01/09/2025
Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session Expanded data analysis from Phase 3 Stage 1 DIAMOND program for OCS-01 eye drops in [...]
Cannara annonce l’octroi d’options d’achat d’actions et d’unités d’actions restreintes (RSU)
01/09/2025
MONTRÉAL, 01 sept. 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara », « la Société », « nous » ou « notre ») ( TSXV : LOVE ) ( OTCQB : LOVFF ) ( FRA : 8CB0) , producteur verticalement intégré de cannabis [...]
Cannara Announces Grant of Options and RSUs
01/09/2025
MONTREAL, Sept. 01, 2025 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“ Cannara ”, “the Company ”, “ us ” or “ we ”) ( TSXV: LOVE ) ( OTCQB: LOVFF ) ( FRA: 8CB0 ), a vertically integrated producer of premium-grade cannabis [...]
Boehringer’s HERNEXEOS® approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC
01/09/2025
This press release is not intended for UK and US media. HERNEXEOS ® (zongertinib tablets) has been approved based on an objective response rate of 71% (N=75), as demonstrated in the Beamion-LUNG 1 clinical trial 1 [...]
Anavar For Women And Men: CrazyBulk Launch Anavar Legal Steroid Alternative For Female Read Dosage, Side Effects, (Before and After Cycle results)
31/08/2025
Anavar is a potent anabolic steroid Alternative Pills for men and women that is popular among bodybuilders and athletes in 2025, also known as oxandrolone, is an orally active substance that is largely popular for its [...]
Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025
31/08/2025
Additional Data from MAPLE-HCM Shows Aficamten Improves Cardiac Structure and Function Compared to Metoprolol; Simultaneous Publication in the Journal of the American College of Cardiology New Analysis Shows Annual [...]
Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025
31/08/2025
Largest Noninterventional Natural History Study of People Under 18 with MYBPC3-associated HCM with More than 200 Participants 93% of MyClimb Participants had the Nonobstructive Form of HCM for Which There Are No [...]
Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress
31/08/2025
– Poster presentation highlights the consistency of reductions in high-sensitivity C-reactive protein with pacibekitug across clinically-meaningful subgroups – – Pacibekitug demonstrated concordant, statistically [...]
Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease
31/08/2025
Compared with tirzepatide, Wegovy ® (semaglutide 2.4 mg) showed a significant 57% greater reduction in the risk of heart attack, stroke or death from any cause, in people with overweight or obesity and cardiovascular [...]
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025
31/08/2025
-- Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanisms of Action -- DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 31, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today [...]
Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular diseas
31/08/2025
Compared with tirzepatide, Wegovy ® (semaglutide 2.4 mg) showed a significant 57% greater reduction in the risk of heart attack, stroke or death from any cause, in people with overweight or obesity and cardiovascular [...]

Pages